Galmed Pharmaceuticals to Report Third Quarter 2020 Financial Results and Provide Business Update on Thursday November 12

Rhea-AI Summary

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) announced a conference call on November 12, 2020, to discuss its financial results for Q3 2020 and provide updates on clinical programs for Aramchol, a treatment for nonalcoholic steatohepatitis (NASH). Aramchol is currently in a Phase 3 clinical trial and has received FDA Fast Track designation. NASH affects an estimated 3% to 5% of the U.S. population and is linked to obesity, leading to severe liver complications.

Positive

• Aramchol is in Phase 3 clinical trials, indicating advanced development.
• The company has received FDA Fast Track designation for Aramchol.

Negative

• None.

TEL AVIV, Israel, Nov. 5, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3 clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis announced today that it will host a conference call and webcast on Thursday, November 12, 2020, to provide an update on current developments with respect to its clinical programs for Aramchol™ and to discuss financial results for the quarter ended September 30, 2020.  

 

 

Conference Call & Webcast:

Thursday November 12, 2020, 8:30 AM ET

Toll Free: 1-877-425-9470
Toll/International: 1-201-389-0878
Israel Toll Free: 1 809 406 247

Conference ID: 13711943  

Webcast: http://public.viavid.com/index.php?id=141982

Replay Dial-In Numbers

Toll Free: 1-844-512-2921
Toll/International: 1-412-317-6671
Replay Pin Number: 13711943
Replay Start: Thursday November 12, 2020, 11:30 AM ET
Replay Expiry: Thursday November 26, 2020, 11:59 PM ET

About Aramchol and Non-alcoholic Steatohepatitis (NASH)

Aramchol (arachidyl amido cholanoic acid) is a novel fatty acid bile acid conjugate, inducing beneficial modulation of intra-hepatic lipid metabolism. Aramchol's ability to modulate hepatic lipid metabolism was discovered and validated in animal models, demonstrating downregulation of the three key pathologies of NASH: steatosis, inflammation and fibrosis. The effect of Aramchol on fibrosis is mediated by downregulation of steatosis and directly on human collagen producing cells. Aramchol has been granted Fast Track designation status by the FDA for the treatment of NASH.

NASH is an emerging world crisis impacting an estimated 3% to 5% of the U.S. population and an estimated 2% to 4% globally. It is the fastest growing cause of liver cancer and liver transplant in the U.S. due to the rise in obesity. NASH is the progressive form of non-alcoholic fatty liver disease that can lead to cardiovascular disease, cirrhosis and liver-related mortality.

About Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases. Our lead compound, Aramchol™, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3 registrational study.

View original content:http://www.prnewswire.com/news-releases/galmed-pharmaceuticals-to-report-third-quarter-2020-financial-results-and-provide-business-update-on-thursday-november-12-301166983.html

SOURCE Galmed Pharmaceuticals Ltd.

FAQ

When will Galmed Pharmaceuticals report its Q3 2020 financial results?

Galmed Pharmaceuticals will report its Q3 2020 financial results on November 12, 2020.

What is the status of Aramchol in clinical trials?

Aramchol is currently in Phase 3 clinical trials for the treatment of NASH.

What is nonalcoholic steatohepatitis (NASH)?

NASH is a progressive form of liver disease affecting 3% to 5% of the U.S. population and can lead to severe complications like liver cancer.

What designation has Aramchol received from the FDA?

Aramchol has received Fast Track designation from the FDA for the treatment of NASH.